在难治性动脉高血压治疗中添加普萘洛尔(APROPRIATE研究):一项随机双盲安慰剂对照试验的研究方案
本研究为在斯里兰卡开展的单中心随机双盲安慰剂对照试验方案,计划纳入200例难治性高血压成人,按1:1随机分配至普萘洛尔40 mg每日三次组或安慰剂组,主要结局为两组间动态血压监测(ABPM)自基线至3个月的平均收缩压与平均舒张压下降幅度的统计学显著差异。研究旨在评估普萘洛尔在难治性高血压中的安全性和有效性。
要点
- 计划纳入200例难治性高血压成人,按1:1随机分配至普萘洛尔40 mg每日三次组或安慰剂组。
- 主要结局为两组间ABPM测得的平均收缩压与平均舒张压自基线下降幅度的统计学显著差异。
- 研究为期3个月,设筛查、1个月、2个月、3个月共4次访视。
核心结论
- 据作者所知,这是首批评估普萘洛尔用于难治性高血压的随机对照试验之一,将为未来大规模多中心临床试验提供必要基础。
- 无论结果阳性或阴性,均应推动指导当前和未来难治性高血压治疗政策的证据发生实质性转变。
研究设计与样本
- 研究为随机、双盲、安慰剂对照临床试验,为期3个月,已获科伦坡大学医学院伦理审查委员会批准。
- 计划招募200例难治性高血压成人,按1:1比例随机分配至试验组和安慰剂组。
- 试验组接受普萘洛尔40 mg每日三次,对照组接受外观相同的安慰剂胶囊,研究药物对研究者和受试者均设盲。
- 访视与评估安排为:筛查(第0次访视)、1个月(第1次访视)、2个月(第2次访视)和3个月(第3次访视)。
- 主要结局为两组间经动态血压监测(ABPM)测得的平均收缩压和平均舒张压自基线下降幅度的统计学显著差异,数据采用SPSS v16分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistant hypertension is defined as an uncontrolled blood pressure despite treatment at best-tolerated doses with at least three antihypertensive agents including a diuretic. It is an emerging public health problem. At present clinical trial data on management of resistant hypertension is limited. Management is largely based on observational studies and expert opinions. Propranolol is a nonselective beta blocker. Several studies have confirmed that propranolol has a significant hypotensive action, both when used alone and as an adjuvant therapy. At present there are no prospective, randomized, clinical studies evaluating the effectiveness of propranolol in patients with resistant hypertension. Therefore, we have designed a prospective randomized trial to evaluate the safety and efficacy of propranolol in patients with resistant hypertension. METHODS/DESIGN: The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a period of 3 months. The study has been approved by the Ethics Review Committee of the Faculty of Medicine, University of Colombo. A total of 200 adults with resistant hypertension will be recruited for the study. They will be randomly assigned to the test and placebo groups on a 1:1 ratio. The test group will receive propranolol 40 mg three times a day and the control group will receive an identical placebo capsule. The study drugs will be double blinded to both investigators and subjects. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit 1), 2 months (visit 2) and 3 months (visit 3). The primary outcomes of the study is to find a statistically significant difference between the fall in mean systolic and mean diastolic blood pressure measured by ABPM (ambulatory blood pressure monitoring) from baseline between the two groups. Data will be analyzed using SPSS v16. DISCUSSION: To our knowledge this is one of the first randomized controlled trials evaluating the effects of propranolol in resistant hypertension. This study will provide the necessary groundwork for future large-scale, multicentered clinical trials. The result, positive or negative, should provide a step change in the evidence guiding current and future policies regarding treatment of resistant hypertension. TRIAL REGISTRATION: Sri Lanka Clinical Trials Registry, identifier: SLCTR/2016/002 . Registered on 27 January 2016; Study protocol version 2.1.
引用
- Constantine GR, Ranasinghe P, Weeratunga P, et al. Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial. Trials. 2017. PMID: 28292320. doi:10.1186/s13063-017-1863-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。